(Q39525614)

12 September 2017

title

Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice (English)

1 reference

12 September 2017

1 reference

1 reference

Dev Karan

1

1 reference

12 September 2017

Seema Dubey

2

1 reference

12 September 2017

Peter Van Veldhuizen

3

1 reference

12 September 2017

Jeffrey M Holzbeierlein

4

1 reference

12 September 2017

Ossama Tawfik

5

1 reference

12 September 2017

J Brantley Thrasher

6

1 reference

12 September 2017

publication date

1 June 2011

1 reference

12 September 2017

1 reference

12 September 2017

volume

3

1 reference

12 September 2017

issue

6

1 reference

12 September 2017

page(s)

735-746

1 reference

12 September 2017

cites work

Cancer statistics, 2010

1 reference

Immunotherapy for prostate cancer: an emerging treatment modality

21 January 2018

1 reference

Immunotherapeutics in development for prostate cancer

21 January 2018

1 reference

Immunization with type 5 adenovirus recombinant for a tumor antigen in combination with recombinant canarypox virus (ALVAC) cytokine gene delivery induces destruction of established prostate tumors

21 January 2018

1 reference

Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

Phase I clinical trial of an adenovirus/prostate-specific antigen vaccine for prostate cancer: safety and immunologic results.

21 January 2018

1 reference

Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical trial results with alpha-N-acetylgalactosamine-O-serine/threonine conjugate vaccine

21 January 2018

1 reference

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

21 January 2018

1 reference

Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers

21 January 2018

1 reference

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

21 January 2018

1 reference

Biological variation of total prostate-specific antigen: a survey of published estimates and consequences for clinical practice.

21 January 2018

1 reference

Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer

21 January 2018

1 reference

Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer

21 January 2018

1 reference

Prostate stem cell antigen: a prospective therapeutic and diagnostic target

21 January 2018

1 reference

A simple method for the rapid generation of recombinant adenovirus vectors

21 January 2018

1 reference

Paradoxical enhancement of CD8 T cell-dependent anti-tumor protection despite reduced CD8 T cell responses with addition of a TLR9 agonist to a tumor vaccine

21 January 2018

1 reference

Identification of an immunodominant H-2D(b)-restricted CTL epitope of human PSA.

21 January 2018

1 reference

Vaccination with a DNA vaccine based on human PSCA and HSP70 adjuvant enhances the antigen-specific CD8+ T-cell response and inhibits the PSCA+ tumors growth in mice

21 January 2018

1 reference

Targeted therapeutic approaches for hormone-refractory prostate cancer

21 January 2018

1 reference

Current status of immunological therapies for prostate cancer.

21 January 2018

1 reference

Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer

21 January 2018

1 reference

Immunotherapy with dendritic cells for prostate cancer

21 January 2018

1 reference

Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma.

21 January 2018

1 reference

Efficient transfer of PSA and PSMA cDNAs into DCs generates antibody and T cell antitumor responses in vivo

21 January 2018

1 reference

Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines

21 January 2018

1 reference

Presentation of tumour antigens by dendritic cells and challenges faced.

21 January 2018

1 reference

Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters

21 January 2018

1 reference

Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer

21 January 2018

1 reference

Induction of PSA-specific CTLs and anti-tumor immunity by a genetic prostate cancer vaccine

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/IMT.11.59

1 reference

12 September 2017

1 reference